Renal Neuroendocrine Tumors: A Single-Center Experience

Joseph A. Scales, MD1, Johann P. Ingimarsson, MD1, Gustavo Westin, MD2, Timothy J. Hobday, MD2, Thorvardur R. Halfdanarson, MD2, 1 Urology, Mayo Clinic, Rochester, MN, 2Medical Oncology, Mayo Clinic, Rochester, MN.

Abstract

Methods

Objectives:
• Despite treatment resistance, the overall survival is long.
• Renal NETs are resistant to systemic therapy.
• Recurrences are common.
• There may be an association with horseshoe kidneys.
• The most common presenting symptoms was pain.
• Renal NETs are rare.
• Responses to systemic therapy were uncommon.

Results

Tumor Characteristics

Grade and Stage

<table>
<thead>
<tr>
<th>Tumor Grade (WHO 2010)</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>5 (36%)</td>
</tr>
<tr>
<td>Grade 2</td>
<td>6 (43%)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>3 (21%)</td>
</tr>
</tbody>
</table>

Time to Recurrence (TTR)

Conclusions

References

4. Lane BR et al. BJU Int. 2007;100:1030-5.